Response to letters regarding article, "using dabigatran in patients with stroke: A practical guide for clinicians"

Stroke

Volumn 43, Issue 5, 2012, Pages

  Alberts, Mark J ^a   Bernstein, Richard A ^a   Naccarelli, Gerald V ^b   Garcia, David A ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DABIGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; THROMBIN TIME; THROMBOSIS PREVENTION;

EID: 84860214360     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.652800     Document Type: Letter

References (3)

1. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8:790-798.
2. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141:1410-1416.
3. Maegdefessel L, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K, Schlitt A. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res. 2010;126:e196-e200.